 |
|
|
| |
A response-guided approach to pegylated interferon alpha-2a (40KD) therapyto improve response rates in HBeAg-negative, genotype D patients
|
| |
| |
Reported by Jules Levin AASLD Nov 5-8 2011 SF
P. Lampertico,1 M. Viganò,1 G.G. Di Costanzo,2 E. Sagnelli,3 M. Fasano,4 V. Di Marco,5 S. Boninsegna,6 P. Farci,7 S. Fargion,1 T. Giuberti,8 V. Rothe,9 L. Regep,10 B. Massetto,11 F. Facchetti,1 M. Colombo1 on behalf of the PegBeLiver Study Group
11st Gastroenterology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy; 2Liver Unit, Cardarelli Hospital, Naples, Italy; 3Infectious Disease Unit, SS. Anna and Sebastiano Hospital, Caserta, Italy; 4Clinic of Infectious Diseases, Università di Bari, Bari, Italy; 5Gastroenterology and Hepatology Unit, (Di.Bi.M.I.S.) University of Palermo, Palermo, Italy; 6Department of Surgical and Gastroenterological Sciences, University of Padua, Padua, Italy; 7Medical Science Department, University of Cagliari, Monserrato, Italy; 8Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero, University of Parma, Parma, Italy; 9IST GmbH, Mannheim, Germany; 10F. Hoffmann-La Roche, Basel, Switzerland; 11 formerly of Roche, Monza, Italy
|
| |
|
|
|
|
|
